 |
|
SATURDAYOctober 19SESSION 18:35 – 8:55 |
Rebat M. Halder Disorders of hyperpigmentation represent a group of cutaneous disease that the dermatologist encounters very commonly. The disorders include melasma, postinflammatory hyperpigmentation, solar lentigines and photoaging. Despite the fact these disorders are common, their treatments remain difficult and sometimes frustrating for both the patient and physician. Several of these disorders appear to occur in a higher frequency in darker skinned ethnic groups and may appear to be more pronounced in these groups. The social impact of these disorders of hyperpigmentation are great. Hydroquinones remain the gold standard for the treatment of hyperpigmentation and have been used for over fifty years. Efficacy is generally related to concentration of the hydroquinone. Another phenolic compound is monobenzoyl either of hydroquinone which is used only to depigment vitiligo. N–acetyl–4–cysteaminylphenol (NCAP) is a new phenolic compound undergoing development for use in hyperpigmentation. Non-phenolic compounds for use in hyperpigmentation are tretinoin, azelaic acid, kojic acid, and arbutin among others. Other nonphenolic compounds in development include licorice extract, mulberry and bearberry. The mechanism of action of phenolic and non-phenolic compounds in the treatment of hyperpigmentation will be reviewed. Lasers and chemicals peels for hyperpigmentation will be discussed briefly. There remains a large void in successful treatments for hyperpigmentation. |